Health Care Services

CARDIFF LEXINGTON CORPORATION

Cardiff Lexington Corp. amends preferred stock terms to cancel redemption rights

Cardiff Lexington Corporation released FY2024 Q3 earnings on November 12, 2025 (EST), actual revenue USD 1.356M, actual EPS USD -0.4723

Cardiff Lexington Corporation released FY2024 9 Months Earnings on November 12, 2025 (EST) with actual revenue of USD 5.149 M and EPS of USD -0.9212

Cardiff Lexington Corporation released FY2025 9 Months Earnings on November 12 (EST), actual revenue USD 8.763 M, actual EPS USD -0.587

Cardiff Lexington Corporation released FY2025 Q3 earnings on November 12, 2025 (EST), actual revenue USD 3.059M, actual EPS USD -0.2138

Cardiff Lexington Corporation released FY2025 Semi-Annual Earnings on August 19, 2025 (EST), with actual revenue of USD 5.705 M and EPS of USD -0.3851

Cardiff Lexington Corporation released FY2024 Q1 earnings on August 19, 2025 (EST), actual revenue USD 2.322M, actual EPS USD -0.3415

Cardiff Lexington Corporation released FY2024 Q2 earnings on August 19 (EST), actual revenue USD 1.472 M, actual EPS USD -0.1073

Cardiff Lexington Corporation released FY2024 Semi-Annual earnings on August 19, 2025 (EST), with actual revenue of USD 3.794 M and EPS of USD -0.3223

Cardiff Lexington Corporation released FY2025 Q2 earnings on August 19, 2025 (EST), with actual revenue of USD 2.789 M and EPS of USD -0.2368

Cardiff Lexington Corporation released FY2025 Q1 earnings on August 19, 2025 (EST) with actual revenue of USD 2.916 M and EPS of USD -0.1363

Cardiff Lexington Corporation released FY2023 Q4 earnings on March 14, 2025 (EST), actual revenue USD 2.377M, actual EPS USD 0

Cardiff Lexington Corporation released FY2023 earnings on March 14 (EST), actual revenue USD 11.85 M, actual EPS USD 0

Cardiff Lexington Corporation released FY2024 Q4 earnings on March 14, 2025 (EST), with actual revenue of USD 3.121 M and actual EPS of USD -0.2315

Cardiff Lexington Corporation released FY2024 earnings on March 14 (EST), actual revenue USD 8.27 M, actual EPS USD -1.1182

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

KORE

EUREKA ACQUISITION CORP COM USD0.0001 A (SUBS/RTS 03/07/2026)

Ensysce Biosciences

Applied Optoelectronics

OneMedNet

INNEOVA

GraniteShares 2x Long DELL Daily ETF

Edesa Biotech

Chaince Digital

Avalon GloboCare

TalkSpace

Cigna

BrightSpring Health Services - Unit

Labcorp

Quest Diagnostics

BrightSpring Health Services

Chemed

Option Care Health

Hinge Health

Hims & Hers Health

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

CDIXD

<p>Cardiff Lexington Corp. has amended the Certificate of Designation for its Series N Senior Convertible Preferred Stock, eliminating provisions for optional and mandatory redemption. This amendment was approved by the required holders of the Series N stock. The original content was published via EDGAR by the U.S. Securities and Exchange Commission.</p>

Reuters

Cardiff Lexington Removes Redemption Rights from Series N Preferred Stock

CARDIFF LEXINGTON CORPORATION(CDIXD.US)

Financial Score

Valuation analysis

Institutional View & Shareholder

Analyst Ratings

Cardiff Lexington Removes Redemption Rights from Series N Preferred Stock